Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer

Terri P McVeigh, Michael J Kerin Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Republic of Ireland Abstract: Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McVeigh TP, Kerin MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Oncotype DX gene expression profiling personalized medicine precision medicine breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4019693c5b824749a62d1efb2f4690df
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4019693c5b824749a62d1efb2f4690df
record_format	dspace
spelling	oai:doaj.org-article:4019693c5b824749a62d1efb2f4690df2021-12-02T02:45:52ZClinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer1179-1314https://doaj.org/article/4019693c5b824749a62d1efb2f4690df2017-05-01T00:00:00Zhttps://www.dovepress.com/clinical-use-of-the-oncotype-dx-genomic-test-to-guide-treatment-decisi-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Terri P McVeigh, Michael J Kerin Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Republic of Ireland Abstract: Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. This test generates a recurrence score between 0 and 100, which correlates with probability of distant disease recurrence. Patients with low-risk recurrence scores (0–17) are unlikely to derive significant survival benefit with adjuvant chemotherapy and hormonal agents derived from using adjuvant hormonal therapy only. Conversely, adjuvant chemotherapy has been shown to significantly improve survival in patients with high-risk recurrence scores (≥31). Trials are ongoing to determine how best to manage patients with recurrence scores in the intermediate range. This review outlines the introduction and impact of Oncotype DX testing on practice; ongoing clinical trials investigating its utility; and challenging clinical scenarios where the absolute recurrence score may require careful interpretation. We also performed a bibliometric analysis of publications on the topics of breast cancer and Oncotype DX as a surrogate marker of acceptability and incorporation of the assay into the management of patients with breast cancer. Keywords: Oncotype DX, gene expression profiling, personalized medicine, precision medicine, breast cancerMcVeigh TPKerin MJDove Medical PressarticleOncotype DXgene expression profilingpersonalized medicineprecision medicinebreast cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 393-400 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Oncotype DX gene expression profiling personalized medicine precision medicine breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Oncotype DX gene expression profiling personalized medicine precision medicine breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 McVeigh TP Kerin MJ Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
description	Terri P McVeigh, Michael J Kerin Discipline of Surgery, Lambe Institute for Translational Research, National University of Ireland Galway, Galway, Republic of Ireland Abstract: Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. This test generates a recurrence score between 0 and 100, which correlates with probability of distant disease recurrence. Patients with low-risk recurrence scores (0–17) are unlikely to derive significant survival benefit with adjuvant chemotherapy and hormonal agents derived from using adjuvant hormonal therapy only. Conversely, adjuvant chemotherapy has been shown to significantly improve survival in patients with high-risk recurrence scores (≥31). Trials are ongoing to determine how best to manage patients with recurrence scores in the intermediate range. This review outlines the introduction and impact of Oncotype DX testing on practice; ongoing clinical trials investigating its utility; and challenging clinical scenarios where the absolute recurrence score may require careful interpretation. We also performed a bibliometric analysis of publications on the topics of breast cancer and Oncotype DX as a surrogate marker of acceptability and incorporation of the assay into the management of patients with breast cancer. Keywords: Oncotype DX, gene expression profiling, personalized medicine, precision medicine, breast cancer
format	article
author	McVeigh TP Kerin MJ
author_facet	McVeigh TP Kerin MJ
author_sort	McVeigh TP
title	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
title_short	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
title_full	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
title_fullStr	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
title_full_unstemmed	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
title_sort	clinical use of the oncotype dx genomic test to guide treatment decisions for patients with invasive breast cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/4019693c5b824749a62d1efb2f4690df
work_keys_str_mv	AT mcveightp clinicaluseoftheoncotypedxgenomictesttoguidetreatmentdecisionsforpatientswithinvasivebreastcancer AT kerinmj clinicaluseoftheoncotypedxgenomictesttoguidetreatmentdecisionsforpatientswithinvasivebreastcancer
_version_	1718402155734368256

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer

Ejemplares similares